Agenerase (Amprenavir)

DO. SEE. HEAR. KNOW. Visit TheBody.com's 2008 World AIDS Day Center >>

HIV/AIDS Basics & Prevention

Just Diagnosed

HIV Treatment

Living With HIV

AIDS Policy & Activism

HIV Around the World

Conference Coverage

Agenerase (Amprenavir)

The Basics | News | Research

See also: Drug Interactions | Medication Side Effects

Brand Name:	Agenerase
Generic Name:	Amprenavir, APV
Adult Single Dose:	Eight 150-mg capsules (twice a day) OR eight 150-mg capsules plus two 100-mg ritonavir capsules (once a day) OR four 150-mg capsules plus one 100-mg ritonavir capsule (twice a day)
Food & Liquid Restrictions:	May be taken with or without food. High-fat meals should be avoided.
Drug Class:	PI

The Basics

An Overview of Agenerase (Amprenavir) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health
Amprenavir (Agenerase) (November 25, 2007)
To read PDF, click here
From AIDS InfoNet
Agenerase (Amprenavir, APV) (January/February 2007)
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
Amprenavir (Agenerase) Simple Fact Sheet (August 15, 2006)
From AIDS Treatment Data Network
Agenerase (Amprenavir) (May 2005)
To read PDF, click here
From The Center for AIDS
Patient Information About Agenerase (Amprenavir) Capsules (PDF) (May 2005)
From GlaxoSmithKline
Patient Information About Agenerase (Amprenavir) Oral Solution (PDF) (May 2005)
From GlaxoSmithKline
Drug Interactions: Amprenavir (August 2004)
From Project Inform

News

Agenerase (Amprenavir) Oral Solution and 50-mg Capsules to Be Discontinued in the U.S. (October 2007)
To read PDF, click here
From GlaxoSmithKline
New Safety Warning for Liquid Amprenavir (May 5, 2000)
In STEP Ezine, from Seattle Treatment Education Project

Research

Dosing Agenerase + Kaletra -- Trying to Juggle, Walk and Chew Gum All at the Same Time (March/April 2004)
A study presented at CROI 2004 bolsters support for the use of therapeutic drug monitoring to customize dosing.
In Positively Aware, from Test Positive Aware Network
Using Genotypic Inhibitory Quotient to Measure Response to Boosted-Amprenavir Regimen (July 15, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.